



City Research Online

City St George's, University of London

Citation: Mulligan, K., Harris, K., Rixon, L. & Burls, A. (2025). A systematic mapping review of clinical guidelines for the management of fatigue in long-term physical health conditions. *Disability and Rehabilitation*, 47(3), pp. 531-548. doi: 10.1080/09638288.2024.2353855

This is the published version of the paper.

This version of the publication may differ from the final published version. To cite this item please consult the publisher's version.

Permanent repository link: <https://openaccess.city.ac.uk/id/eprint/32834/>

Link to published version: <https://doi.org/10.1080/09638288.2024.2353855>

Copyright and Reuse: Copyright and Moral Rights remain with the author(s) and/or copyright holders. Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge, unless otherwise indicated, provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way. For full details of reuse please refer to [City Research Online policy](#).



A systematic mapping review of clinical guidelines for the management of fatigue in long-term physical health conditions

Kathleen Mulligan, Katherine Harris, Lorna Rixon & Amanda Burls


To cite this article: Kathleen Mulligan, Katherine Harris, Lorna Rixon & Amanda Burls (04 Jun 2024): A systematic mapping review of clinical guidelines for the management of fatigue in long-term physical health conditions, *Disability and Rehabilitation*, DOI: [10.1080/09638288.2024.2353855](https://doi.org/10.1080/09638288.2024.2353855)

To link to this article: <https://doi.org/10.1080/09638288.2024.2353855>



© 2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group




[View supplementary material](#) 




Published online: 04 Jun 2024.



[Submit your article to this journal](#) 



[View related articles](#) 



[View Crossmark data](#) 

A systematic mapping review of clinical guidelines for the management of fatigue in long-term physical health conditions

Kathleen Mulligan^{a,b}, Katherine Harris^c, Lorna Rixon^a and Amanda Burls^a

^aSchool of Health and Psychological Sciences, City, University of London, London, United Kingdom; ^bEast London NHS Foundation Trust, London, United Kingdom; ^cCentre for Genomics and Child Health, the Blizard Institute, Queen Mary University of London, London, United Kingdom

ABSTRACT

Purpose: Despite a high prevalence of fatigue and its importance to patients, many people with long-term conditions do not receive fatigue management as part of their treatment. This review is aimed to identify clinical guidance for the management of fatigue in long-term physical health conditions.

Methods: A systematic mapping review was conducted in accordance with Social Care Institute for Excellence systematic review guidance. Bibliographic databases and guideline repositories were searched for clinical guidelines for long-term conditions, published between January 2008 and July 2018, with a search for updates conducted in May 2023. Data were extracted on the recommendations made for managing fatigue and, where cited, the underlying research evidence used to support these recommendations was also extracted.

Results: The review included 221 guidelines on 67 different long-term conditions. Only 30 (13.6%) of the guidelines contained recommendations for managing fatigue. These were categorised as clinical (e.g. conduct further investigations), pharmacological, behavioural (e.g. physical activity), psychological, nutritional, complementary, environmental, and multicomponent. The guidelines rated much of the evidence for fatigue management as fairly low quality, highlighting the need to develop and test fatigue-management strategies in high-quality trials.

Conclusion: This review highlights that management of fatigue is a very important neglected area in the clinical guidelines for managing long-term conditions.

ARTICLE HISTORY

Received 27 November 2023

Revised 3 May 2024

Accepted 4 May 2024

KEYWORDS

Fatigue; long-term conditions; systematic review; mapping review; clinical guidelines

> IMPLICATIONS FOR REHABILITATION

- Fatigue is a common and debilitating symptom of many long-term physical health conditions; however, many people do not receive treatment for fatigue.
- This mapping review found that very few clinical guidelines contain recommendations for managing fatigue, even where published evidence exists.
- It is essential that developers of clinical guidelines address this important neglected area.



Introduction


Fatigue is a common and debilitating symptom of many long-term physical health conditions, including musculoskeletal, neurological, and cardiovascular conditions. It is not ordinary tiredness that is resolved by rest but is described by patients as overwhelming, and for many it is the most troubling symptom of their disease [1–4]. Estimated prevalence of fatigue in people with long-term conditions (LTCs) ranges from about one-fifth to >90% (see [Supplementary table 1](#)).

Fatigue has a significant negative impact on quality of life across many LTCs [5–12]. It is an important predictor of healthcare utilisation [13] and mortality [14,15] and has a high economic cost to society as a major cause of work disability [2,16–18]. Treatment is therefore essential to help reduce symptoms and/or help people manage fatigue to lessen its impact on their lives. However, many people with LTCs do not receive treatment for fatigue. For example,

a survey of adults with rheumatoid arthritis (RA) found that 89% of respondents experienced fatigue but only 2% had attended a fatigue-management intervention [19]. A survey of people with multiple sclerosis (MS) found that 90.3% reported experiencing fatigue but only 30.8% reported being offered any pharmacological or non-pharmacological treatment for their fatigue [20]. Both of these reports [19,20] stressed the importance of clinical practice guidelines in guiding treatment and emphasised that the guidelines for these conditions need to be strengthened to clearly reflect the best available evidence for managing fatigue, summarising both beneficial and ineffective treatments.

Approaches to help manage fatigue include pharmacological and non-pharmacological interventions. There is evidence for the efficacy of some interventions [21–23], however, these interventions are not necessarily considered in clinical guidelines [24,25]. For example, a Cochrane review of biologic agents for fatigue in

CONTACT Kathleen Mulligan  kathleen.mulligan.1@city.ac.uk  School of Health and Psychological Sciences, City, University of London, Northampton Square, London, EC1V 0HB, UK

 Supplemental data for this article can be accessed online at <https://doi.org/10.1080/09638288.2024.2353855>.

© 2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.

RA concluded, based on evidence they rated as moderate quality, that biologic agents produce small to moderate benefit [26]. A Cochrane review in RA concluded that physical activity interventions, which they rated as moderate quality, and psychosocial interventions (such as cognitive behavioural therapy and mindfulness therapy) produce small beneficial effects, although evaluations of psychosocial interventions were rated as low quality [21]. A systematic review of aerobic exercise for people with systemic lupus erythematosus (SLE), in which most studies were rated to have low or very low risk of bias, reported significant reductions in fatigue with moderate to high effect sizes [27]. However, some recent SLE guidelines do not contain recommendations on managing fatigue [28]. Given these limitations, we wanted to review the recommendations for managing fatigue across other long-term physical health conditions to see if there could be any shared learning across the condition-specific guidelines on how to manage this frequently reported symptom, or whether lack of treatment recommendations is common across conditions.

The aim of this review was to identify and categorise the clinical guidance, both pharmacological and non-pharmacological, that exists for the management of fatigue in long-term physical health conditions and to identify any gaps in this guidance.

Materials and methods

Design

A systematic mapping review was conducted in accordance with Social Care Institute for Excellence systematic review guidance [29]. This type of review does not aim to rate the evidence in an area but rather to provide a comprehensive description of the literature available on a topic and identify gaps in that literature [29].

Inclusion criteria

Clinical guideline documents were included if they related to the management of a long-term physical health condition in adults (≥ 18 years old).

To ensure that we were as inclusive as possible, we did not set exclusion criteria based on whether or not fatigue was a recognised symptom of the LTC. Instead, we referenced literature on fatigue prevalence data across all of the LTCs for which we identified guidelines (Supplementary table 1).

If a guideline was superseded by a more up to date guideline from the same organisation, only the most recent guideline was included.

Exclusion criteria

We aimed to examine clinical guidelines for the comprehensive management of a LTC and therefore guidelines that had a narrow focus, for example, solely on imaging, administration of a pharmacological agent or surgical guidance for a LTC, were excluded.

Guidelines were excluded if they related to LTCs resulting from accident or injury, rather than disease, mental health conditions or developmental disorders. Guidelines relating to cancer were excluded because a systematic review of clinical guidelines for the management of cancer-related fatigue has already been published [30]. Guidelines for myalgic encephalomyelitis/chronic fatigue syndrome were also excluded as fatigue is the illness itself rather than an effect of a distinct LTC.

Search methods

The following databases were searched from January 2008 to July 2018 to identify published clinical guidelines:

- AMED
- Embase
- EBM Reviews – ACP Journal Club
- CINAHL
- Medline

A period of 10 years was considered sufficient to identify current guidelines. An update was conducted in May 2023, when all included guidelines were checked to ensure that the latest version had been identified.

The following electronic repositories were also searched:

- Australian National Health and Medical Research Council clinical practice guidelines [31]
- Canadian Medical Association InfoBase of clinical practice guidelines [32]
- Guidelines International Network [33]
- National Institute for Health and Care Excellence [34]
- New Zealand Guidelines group [35]
- Scottish Intercollegiate Guidelines Network [36]

The search terms are described in Appendix A. Terms relating to LTCs included the MeSH terms “chronic disease” and “chronic illness.” The individual conditions were also searched in all fields; the names of all known LTCs could not be included as this would be unmanageable, therefore common LTCs and those known to have high prevalence of fatigue were included. “Guideline” with the truncation symbol “*” or “guidance” was searched in the Title.

The clinical guidelines repositories were searched for each of the individual conditions listed in the search in Appendix A. A search for “fatigue” was also conducted in the clinical guidelines databases.

Data extraction (selection and coding)

Selection of studies

Studies identified in bibliographic databases were imported into Rayyan systematic review software [37] and duplicates removed. Guidelines identified in the clinical guideline repositories were entered into an Excel file. Two review authors (KH and KM) independently screened studies using the inclusion and exclusion criteria, first applied to title and abstract screening, and then to the full-texts of papers that had not been excluded on title and abstract. Disagreements were resolved through discussion.

Data extraction and management

Data extraction was performed by one reviewer with 10% checked by a second reviewer, using a data extraction sheet developed by the research team. Data were extracted for:

- Authors
- Country of origin
- Publication date
- Guideline body

- Global/National/Local Guideline
- Long-term condition
- Guideline recommendations made for managing fatigue and, where cited, the underlying research evidence used to support these recommendations was also extracted. If a guideline included recommendations for treating children and adults, only recommendations relating to adults were extracted. Recommendations relating only to the acute phase of a disease (e.g. in the emergency room) were not extracted.

Data synthesis

A narrative synthesis was conducted. The number of guidelines and percentage that made fatigue recommendations were summarised numerically for each LTC. The recommendations for managing fatigue were categorised by the type of intervention recommended. Categorisation was conducted by KM and checked by LR.

Risk of bias (quality) assessment

A quality assessment of the identified guidelines, such as AGREE II [38], was not conducted. AGREE II criteria are designed to be applied to the full guideline and would therefore not reflect the quality of specific guidance in relation to fatigue. Furthermore, it is not an aim of this review to make treatment recommendations. Mapping reviews aim to provide a comprehensive description of the literature on a topic and identify gaps in the evidence rather than to rate the evidence; it is therefore not usual to include quality assessments in mapping reviews [29].

Results

Searches identified 4444 publications, of which 221 guidelines relating to 67 different LTCs met the inclusion criteria (Figure 1).

Only 30 (13.6%) guidelines, relating to 19 (28.4%) LTCs, contained recommendations for managing fatigue (Figure 2). If we exclude guidelines related to LTCs where no data on fatigue prevalence were found (30 guidelines related to 21 LTCs – see Supplementary table 1), this still gives only 30/191 (15.7%).

The 30 guidelines that contained fatigue recommendations (Table 1) mostly related to cardiovascular ($n=6$ guidelines), post-infection ($n=5$), and neurological conditions ($n=5$). Guidelines with no fatigue recommendations are listed in Supplementary table 2.

Of the 30 guidelines that included fatigue recommendations, the amount of guidance given was mostly minimal. Only seven of the guidelines laid out what might be considered fairly comprehensive guidance [39–45]. The guidance that addressed fatigue focused on a number of different approaches, which we grouped into categories, based on the type of intervention recommended, and guided by similar categories reported elsewhere in the literature [46,47]. The categories were:

- Clinical – e.g. investigations, referrals
- Pharmacological – guidance re medications
- Information/education - provision of basic information about fatigue
- Psychological/Psychosocial e.g. coping skills, cognitive behavioural therapy
- Behavioural (focused on change in patients' behaviour) e.g. activity pacing, physical activity, dietary behaviour (such as advice about fasting during Ramadan)
- Nutritional e.g. taking dietary supplements
- Environmental (physical) e.g. warmth
- Complementary therapies (defined as "treatment that falls outside of mainstream healthcare" [48]) e.g. acupuncture

The findings for these categories are summarised below:

Clinical – Of the 30 guidelines that made fatigue recommendations, 17 (56.7%) recommendations were categorised as "Clinical" [39,40,43–45,49,50,52–61]. These mostly involved recommendations to consider modifiable contributory factors, to conduct further investigations, and/or to refer for further input.

Pharmacological – Sixteen guidelines (53.3%) [39–45,50,55,57,62–67] made recommendations categorised as "Pharmacological," most of which related to the review/adjustment of medication that may have contributed to symptoms of fatigue. Eight guidelines for fibromyalgia [41], human immunodeficiency virus (HIV) [55], MS [43], post-polio syndrome [67], Sjogren's syndrome [42], SLE [57], and Stroke [44,45] made recommendations about 19 pharmacological agents for the treatment of fatigue. Supplementary figure 1 plots the strength of guideline recommendation for each treatment according to whether it should/should not be given or could be considered for some patients/situations, and the strength with which each recommendation was made. It can be seen that all of the strong recommendations related to treatments that should not be given, while the recommendations in favour of treatments were weak or not classified. Only hydroxychloroquine and modafinil were recommended for consideration in more than one LTC – hydroxychloroquine for SLE in patients with normal renal and liver function [57] and in selected situations for Sjogren's Syndrome [42] and modafinil in MS [43] and stroke [44,45] (but for the latter, one guideline advised it should only be provided in the context of a clinical trial).

Supplementary figure 2 plots the strength of guideline recommendations/quality of evidence reported for non-pharmacological treatments, which are summarised below.

Information – Five guidelines (16.7%) on heart failure [61], MS [43], and stroke [44,45,59] recommended provision of information regarding fatigue, including potential fatigue triggers.

Psychological – Eight guidelines (27.6%) made recommendations categorised as "Psychological" [39–41,44,45,51,68,69]. These included relaxation therapy [45,51], coping strategies [40,45], stress management [39], psychotherapy [39], mindfulness-based training [44,69], cognitive behavioural therapy/techniques [44,68], building acceptance and adjustment [45], and communication of needs to others [44]. The guidelines were for heart failure, inflammatory bowel disease, cholestatic liver disease, fibromyalgia, stroke, and chronic obstructive pulmonary disease (COPD). Guidance for psychological treatments mostly consisted of weak recommendations based on low-quality evidence.

Behavioural – Seventeen guidelines (58.6%) made recommendations categorised as "Behavioural." The most common was regarding physical activity [39,41–45,50,51,60,67,69,70], which was recommended across several LTCs, including heart failure, inflammatory bowel disease, post-polio syndrome, fibromyalgia, RA, Sjogren's syndrome, MS, stroke, and COPD. Several fatigue-specific physical activity recommendations were based on limited or low-quality evidence, as rated by the guideline authors. Two exceptions were for COPD, where pulmonary rehabilitation was strongly recommended based on evidence from systematic reviews or randomised controlled trials (RCTs) [60] and for heart failure, where aerobic endurance or interval training was recommended for people in New York Heart Association




Figure 1. PRISMA flow diagram.

(NYHA) Classes II–III, based on Level 1 (systematic review) evidence [51]. Exercise was advised against in some patients with heart failure.

Other behavioural recommendations included pacing of rest and activity [44,45,67,71] and sleep hygiene practices [40,44,68].

Specific dietary advice was given regarding diabetes [72] and amyotrophic lateral sclerosis (ALS) [58]. Advice for diabetes was to break fasting during Ramadan if symptoms of hyperglycaemia, such as fatigue, were experienced; the evidence on which this was based is unclear. Advice for ALS was to eat several small meals a day, which was considered a good practice point.

Some behavioural advice was vague, for example, self-management education was recommended for COPD but without specifying how fatigue management should be addressed [69].

Nutritional – Three guidelines (10.0%) made recommendations that we categorised as “Nutritional.” A guideline for neurological conditions [58], made a “good practice point” recommendation for meal enrichment/oral supplementation for prevention of malnutrition in MS and, if weight loss progresses, in ALS. An MS guideline recommended explaining that there is no evidence for a specific diet to help MS-related fatigue [43]. A guideline for COPD [69] recommended




Figure 2. Number of guidelines identified by condition, with and without recommendations for managing fatigue.

nutritional support to improve fatigue (level of evidence/strength of recommendation unclear).

Complementary – Two guidelines (6.7%), one for fibromyalgia [41] and one for stroke [45], made recommendations regarding complementary therapies. A guideline for fibromyalgia made a

“weak” recommendation for use of acupuncture and a weak recommendation against S-adenosyl methionine, based on Level 1A evidence (systematic reviews). A stroke guideline [45] recommended that acupuncture should only be provided in the context of a clinical trial.

Table 1. Guidelines containing recommendations for managing fatigue.

Condition	Guideline organisation, date, and title	Summary of recommendations contained in the guidelines	Level of evidence on which guidance reported to be based and strength of recommendation
Cardiovascular conditions			
1. Chronic rheumatic heart disease	RHDAustralia (ARF/RHD writing group), 2020. The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease (3rd edition) [49]	<ul style="list-style-type: none"> • Clinical <ul style="list-style-type: none"> ◦ Worsening fatigue in a pregnant or post-partum woman at higher risk of diagnosed with RHD should be investigated with an echocardiogram. 	GRADE 1C – Strong recommendation but some evidence base of low quality
2. Heart failure	Canadian Cardiovascular Society, 2017. 2017 Comprehensive update of the Canadian Cardiovascular Society Guidelines for the management of heart failure [50]	<p>Managing options for fatigue as a symptom of advanced heart failure (HF)</p> <ul style="list-style-type: none"> • Clinical <ul style="list-style-type: none"> ◦ Consider depression, sleep disordered breathing, or other comorbidities • Pharmacological management <ul style="list-style-type: none"> ◦ Optimized Canadian Cardiovascular Society HF guideline therapy • Behavioural <ul style="list-style-type: none"> ◦ Rehabilitation/physical activity 	Guidance given as “Practical tips”
3. Heart failure	2022 AHA/ACC/HFSA guideline for the management of heart failure [61]	<ul style="list-style-type: none"> • Clinical <ul style="list-style-type: none"> ◦ Provide palliative and supportive care which can partially remediate symptoms including fatigue 	Recommendation 1 [Strong]; Level of Evidence C – Limited Data
4. Heart failure	Dutch Royal Society for Physiotherapy 2014. Exercise-based cardiac rehabilitation in patients with chronic heart failure: A Dutch practice guideline [51]	<p>Generic (reducing fatigue is given as a goal of rehabilitation):</p> <ul style="list-style-type: none"> • Behavioural <ul style="list-style-type: none"> ◦ Aerobic endurance or interval training for people in NYHA Classes II–III ◦ High-intensity interval training (HIIT) for those in low risk <p>■ But caution re HIIT in those with high risk of cardiac overload</p> <ul style="list-style-type: none"> ◦ Strength training for stable chronic heart failure (CHF) <ul style="list-style-type: none"> ■ But caution re strength training in those with left ventricular ejection fraction (LVEF) < 35% ◦ Inspiratory muscle training ◦ Continuation of physically active lifestyle <ul style="list-style-type: none"> • Psychological <ul style="list-style-type: none"> ◦ Relaxation therapy <p>Fatigue specific:</p> <ul style="list-style-type: none"> • Behavioural <ul style="list-style-type: none"> ◦ Severe fatigue would be a sign of excessive strain in which case it is recommended that exercise should be discontinued or intensity decreased • Information <ul style="list-style-type: none"> ◦ Information and advice to promote effective ways of dealing with symptoms, including fatigue (but detail is not included on what the information and advice should be) 	<p>Level 1 (Systematic review or at least two independent randomised, double-blind, comparative clinical trial of good quality and sufficient sample size)</p> <p>Level 2 (one randomised, double-blind, comparative clinical trial of good quality and sufficient sample size or at least two independent comparative studies)</p> <p>Level 4 (expert opinion)</p> <p>Level 1</p> <p>Level 4</p> <p>Level 2</p> <p>Levels 1–2</p> <p>Levels 2 and 3 (3 – one comparative or non-comparative study)</p> <p>Evidence relating to fatigue-specific recommendations not reported.</p>
5. Heart failure	European Society of Cardiology, 2021. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association of the ESC [62]	<ul style="list-style-type: none"> • Pharmacological <ul style="list-style-type: none"> ◦ In treatment of amyloidosis and HF, avoid calcium channel blockers, which may cause fatigue 	Unclear

Condition	Guideline organisation, date, and title	Summary of recommendations contained in the guidelines N.B. this information has been condensed and does not provide the full information in the guideline, for which it is necessary to access the source documents.	Level of evidence on which guidance reported to be based and strength of recommendation
6. Heart failure	Scottish Intercollegiate Guidelines Network 2016. Management of chronic heart failure SIGN 147 [63]	<ul style="list-style-type: none"> Pharmacological <ul style="list-style-type: none"> In patients taking beta blockers, review/ adjustment of medication if symptoms worsen (tiredness, fatigue, breathlessness) Behavioural <ul style="list-style-type: none"> Break the fast if symptoms of hyperglycaemia (which include fatigue) occur Pharmacological <ul style="list-style-type: none"> Less intensive treatment recommended (target HbA1c between 7% and 8%) for patients >65 years who exhibit fragility, defined as significant fatigue and severe restrictions on mobility or strength, who are at greater risk of falls and institutionalization Clinical <ul style="list-style-type: none"> Likely to be ameliorated by phlebotomy 	Recommendation re fatigue given as practical guidance for use of beta blockers Unclear re fatigue recommendation GRADE [84]: Weak recommendation in favour, based on expert consensus
7. Diabetes and other endocrinal, nutritional, and metabolic conditions	International Diabetes Federation and DAR International Alliance, 2021. Diabetes and Ramadan: practical guidelines [72]	<ul style="list-style-type: none"> Colombian Ministry of Health and Social Welfare 2016. Clinical practice guideline for the prevention, early detection, diagnosis, management, and follow up of type 2 diabetes mellitus in adults [64] 	
8. Type 2 diabetes	American Association for the Study of Liver Diseases 2011. Diagnosis and management of haemochromatosis: 2011 Practice guideline by the American Association for the Study of Liver Diseases [52]	<ul style="list-style-type: none"> Clinical <ul style="list-style-type: none"> Likely to be ameliorated by phlebotomy 	GRADE: Strong recommendation for phlebotomy (not fatigue specific) based on high-quality evidence "further research is unlikely to change confidence in the estimate of the clinical effect" GRADE [84]: Ungraded best practice statement
9. Haemochromatosis	The Endocrine Society 2016. Diagnosis and treatment of primary adrenal insufficiency: An Endocrine Society clinical practice guideline [53]	<ul style="list-style-type: none"> Clinical <ul style="list-style-type: none"> In patients with primary AI who are pregnant, monitor at least once per trimester for clinical symptoms and signs of glucocorticoid over- and under-replacement, including fatigue. 	
10. Adrenal insufficiency	British Society of Gastroenterology, 2019. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults [39]	<ul style="list-style-type: none"> Clinical/Pharmacological <ul style="list-style-type: none"> Ask about symptoms of fatigue Investigate for subclinical disease activity Consider potentially modifiable factors (sleep pattern, medication side effects, anaemia, iron deficiency, electrolyte disturbance, thyroid dysfunction, vitamin D and B12 deficiency, psychological symptoms) Those with disabling fatigue in whom no correctable metabolic deficiency or active disease is found, or where fatigue persists despite addressing these factors, may be directed to non-pharmacological therapies (see Behavioural/Psychological below) Behavioural <ul style="list-style-type: none"> Graded exercise Psychological <ul style="list-style-type: none"> Supportive psychotherapy, stress management 	GRADE Good Practice Recommendations GRADE weak recommendation based on low-quality evidence GRADE weak recommendation based on low-quality evidence Clinical practice point
11. Digestive tract conditions Inflammatory bowel disease	Centre for Research Excellence in Polycystic Ovary Syndrome, European Society of Human Reproduction and Embryology and American Society of Reproductive Medicine, 2018. International evidence-based guideline for the assessment and management of polycystic ovary syndrome 2018 [54]	<ul style="list-style-type: none"> Clinical <ul style="list-style-type: none"> If women with polycystic ovary syndrome have symptoms of obstructive sleep apnoea and a positive screen, consider referral to specialist centre for further evaluation 	
12. Gynaecological conditions Polycystic ovary syndrome			

(Continued)

Table 1. Continued.

Condition	Guideline organisation, date, and title	Summary of recommendations contained in the guidelines N.B. this information has been condensed and does not provide the full information in the guideline, for which it is necessary to access the source documents.	Level of evidence on which guidance reported to be based and strength of recommendation
13. HIV Infections	British Columbia Centre for Excellence in HIV/AIDS, 2021. Primary care guidelines for the management of HIV/AIDS in adults in British Columbia [55]	<ul style="list-style-type: none"> Clinical / Pharmacological <ul style="list-style-type: none"> Assess morning serum total testosterone level in HIV-positive cisgender men presenting with fatigue as symptom of hypogonadism Testosterone replacement indicated only for symptomatic cisgender men with total testosterone levels <10 mmol/L Pharmacological <ul style="list-style-type: none"> Patients (particularly those aged >65 years) who experience symptoms of hepatotoxicity (which can include fatigue) from treatment of latent TB infection, should contact their healthcare providers, and if there is a delay in doing so, immediately stop treatment. 	Adapted from Strength of Recommendation Taxonomy [85]: B – Moderate quality evidence D – Very low quality evidence
14. HIV	British HIV Association, 2021. British HIV Association guidelines for the management of tuberculosis in adults living with HIV 2018 (2021 interim update) [65]	<ul style="list-style-type: none"> Pharmacological <ul style="list-style-type: none"> If criteria for anti-TB drug-induced liver injury are fulfilled (symptoms of which may include fatigue), potentially hepatotoxic drugs should be stopped and patient evaluated Intralesional interferon is not recommended for first-line treatment because of potential for adverse effects, which include fatigue 	Unclear
15. HIV	National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America 2023. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV [66]	<ul style="list-style-type: none"> Pharmacological <ul style="list-style-type: none"> If criteria for anti-TB drug-induced liver injury are fulfilled (symptoms of which may include fatigue), potentially hepatotoxic drugs should be stopped and patient evaluated Intralesional interferon is not recommended for first-line treatment because of potential for adverse effects, which include fatigue 	Strong recommendation based on expert opinion <ul style="list-style-type: none"> Weak recommendation based on expert opinion
16. HIV	European AIDS Clinical Society 2020. European AIDS Clinical Society Guidelines Version 10.1 [56]	<ul style="list-style-type: none"> Clinical <ul style="list-style-type: none"> In people living with HIV who are frail, screen for, and address modifiable causes of fatigue (reference given to frailty clinical guidelines). If fatigue present as symptom of hypogonadism, refer to endocrinologist / andrologist / gynaecologist 	Not reported "All recommendations are evidence-based whenever possible and based on expert opinions in the rare instances where adequate evidence is unavailable. The Guidelines do not provide formal grades of evidence"
17. Post-polio syndrome	European Federation of Neurological Societies 2011. Post-Polio syndrome [67]	<ul style="list-style-type: none"> Pharmacological <ul style="list-style-type: none"> No definitive therapeutic effect for pyridostigmine, prednisolone, amantadine, modafinil Behavioural <ul style="list-style-type: none"> Supervised muscular training, both isokinetic and isometric Periods of rest between series of exercises Environmental <ul style="list-style-type: none"> Training in a warm climate 	EFNS scheme for guidelines [86] Pharmacological – IA (established as not useful based on adequate RCTs/systematic review) Supervised training – IIB and IIIB (established as probably useful based on cohort study, suboptimal RCT, other controlled trial) Rest – not reported Environmental – IB (established as probably useful based on adequate RCT/systematic review)

Condition	Guideline organisation, date, and title	Summary of recommendations contained in the guidelines N.B. this information has been condensed and does not provide the full information in the guideline, for which it is necessary to access the source documents.	Level of evidence on which guidance reported to be based and strength of recommendation
18. Liver conditions Cholestatic liver diseases	European Association for the Study of the Liver 2009. EASL clinical practice guidelines: Management of cholestatic liver diseases [40]	<ul style="list-style-type: none"> • Clinical <ul style="list-style-type: none"> o Exclude associated disease or medication use characterised by fatigue o Liver transplantation is not appropriate for treatment of fatigue in the absence of other indications • Pharmacological <ul style="list-style-type: none"> o Consider minimising factors likely to exacerbate autonomic dysfunction such as excessive anti-hypertensive medication • Behavioural <ul style="list-style-type: none"> o Consider minimising factors likely to exacerbate sleep disturbance such as caffeine in evenings • Psychological <ul style="list-style-type: none"> o Consider psychological support to assist with development of coping strategies 	Adapted from GRADE [84]: Weak recommendation based on expert opinion Strong recommendation based on expert opinion Weak recommendation based on expert opinion Weak recommendation based on expert opinion Weak recommendation based on low-quality evidence
19. Musculoskeletal conditions Fibromyalgia	European League Against Rheumatism 2017. EULAR revised recommendations for the management of fibromyalgia [41]	<ul style="list-style-type: none"> • Pharmacological <ul style="list-style-type: none"> o Amitriptyline (at low dose) o Pregabalin o Monoamine oxidase inhibitors o Duloxetine and milnacipran o Selective serotonin reuptake inhibitor o Sodium oxybate • Behavioural <ul style="list-style-type: none"> o Meditative movement therapies (qigong, yoga, tai chi) • Psychological <ul style="list-style-type: none"> o Biofeedback • Multicomponent <ul style="list-style-type: none"> o Combined behavioural/psychological with exercise • Complementary <ul style="list-style-type: none"> o Acupuncture o S-adenosyl methionine • Behavioural <ul style="list-style-type: none"> o Provide information about the importance of exercise and a healthy lifestyle o Supervise and encourage the patient during exercise if there are RA-specific barriers such as fatigue o Any form of exercise therapy, unsupervised at least 50% of the time 	Based on systematic reviews (with or without meta-analysis): Weak recommendation for Weak recommendation for Weak recommendation against Weak recommendation for Strong recommendation against Weak recommendation against Weak recommendation against Weak recommendation for Weak recommendation for Weak recommendation against Based on literature review but otherwise unclear Based on literature review but otherwise unclear Implementation deemed acceptable and feasible, although estimated effects uncertain, based on low-quality evidence Effectiveness and quality of evidence re fatigue could not be determined Implementation deemed acceptable and feasible, although no estimated effects available Unknown – no studies Unknown – no studies Unknown – no studies Unknown – no studies Unknown – no studies
20. Rheumatoid arthritis	Royal Dutch Society for Physical Therapy, 2018. KNGF guideline rheumatoid arthritis [70]	<ul style="list-style-type: none"> o Any form of fully supervised exercise therapy o Any form of fully supervised exercise therapy for patients with serious disease progression o Frequency of exercise therapy o Intensity of exercise therapy o Type of exercise therapy o Duration of exercise therapy o Hand exercises o Exercise therapy on land versus in water 	Based on literature review but otherwise unclear Based on literature review but otherwise unclear Implementation deemed acceptable and feasible, although estimated effects uncertain, based on low-quality evidence Effectiveness and quality of evidence re fatigue could not be determined Implementation deemed acceptable and feasible, although no estimated effects available Unknown – no studies Unknown – no studies Unknown – no studies Unknown – no studies Unknown – no studies

(Continued)

Table 1. Continued.	Summary of recommendations contained in the guidelines	Level of evidence on which guidance reported to be based and strength of recommendation
<p>Condition</p> <p>21. Sjogren's syndrome</p>	<p>Guideline organisation, date, and title</p> <p>Sjögren's Syndrome Foundation 2017. Treatment guidelines for rheumatologic manifestations of Sjögren's syndrome: Use of biologic agents, management of fatigue, and inflammatory musculoskeletal pain [42]</p> <ul style="list-style-type: none"> • Pharmacological <ul style="list-style-type: none"> o Dehydroepiandrosterone is not recommended o Hydroxychloroquine may be considered in selected situations o Neither etanercept nor infliximab is recommended • Behavioural <ul style="list-style-type: none"> o Education about self-care measures should include advice about exercise • Clinical <ul style="list-style-type: none"> o Complications of lupus, including chronic fatigue, should be managed according to national and international guidelines • Pharmacological <ul style="list-style-type: none"> o For patients with normal renal and liver function, hydroxychloroquine, can be used up to 6.5 mg/kg/day 	<p>Modified GRADE [84]:</p> <p>Strong recommendation against, based on two well-recommended RCTs.</p> <p>Weak recommendation for, based on experience in patients with systemic lupus, one uncontrolled, retrospective study and one RCT in Sjögren's syndrome.</p> <p>Strong recommendation against, based on insufficient data and experience</p> <p>Strong recommendation for based on one small RCT plus evidence from other musculoskeletal conditions</p> <p>Not reported</p>
<p>22. Systemic lupus erythematosus</p>	<p>British Society for Rheumatology 2018. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults [57]</p>	<p>Not reported</p>
<p>Neurological conditions</p> <p>23. Multiple sclerosis</p>	<p>National Institute for Health and Care Excellence (NICE) Multiple sclerosis in adults: management 2022 ng220 [43]</p> <ul style="list-style-type: none"> • Clinical <ul style="list-style-type: none"> o Assess fatigue, including potential causes other than MS • Pharmacological <ul style="list-style-type: none"> o Consider: <ul style="list-style-type: none"> ■ Amantadine ■ Modafinil ■ Selective serotonin reuptake inhibitor o Do not use vitamin B12 injections o Do not offer hyperbaric oxygen • Information • Explain potential precipitants of fatigue in MS • Behavioural <ul style="list-style-type: none"> o Consider supervised exercise programmes involving moderate progressive resistance training and aerobic exercise o Consider vestibular rehabilitation o Advise that aerobic, balance and stretching exercises including yoga may be helpful o Encourage to keep exercising after treatment programmes end o Help continue to exercise, e.g. referral to exercise referral schemes o Offer treatment based on person preference and ability to continue the activity after end of treatment programme • Nutritional <ul style="list-style-type: none"> o Explain there is no evidence for specific diet to help fatigue but follow healthy diet for general health • Multicomponent <ul style="list-style-type: none"> o Consider a combination of supervised aerobic and moderate progressive resistance activity combined with cognitive behavioural techniques for fatigue in people with moderately impaired mobility o Offer discussion about self-management that could include goals, energy conservation, lifestyle factors, use of stress management approaches such as mindfulness and cognitive behavioural techniques 	<p>Informal consensus</p> <p>SIGN [87] A1++ At least one high-quality meta-analysis</p> <p>Amantadine – very low quality evidence</p> <p>Modafinil – consensus based on clinical experience and low-quality evidence</p> <p>SSRI – very low quality evidence</p> <p>Vit B12 – no evidence for use</p> <p>Hyperbaric oxygen – lack of evidence, clinical experience, and high cost</p> <p>Clinical experience</p> <p>Mostly low or very low quality evidence</p>
		<p>Lack of available evidence on specific diets</p>
		<p>Evidence ranged from very low to high quality</p>
		<p>Self-management discussion – insufficient evidence to recommend formal programmes but recommendation based on clinical experience</p>

Condition	Guideline organisation, date, and title	Summary of recommendations contained in the guidelines N.B. this information has been condensed and does not provide the full information in the guideline, for which it is necessary to access the source documents.	Level of evidence on which guidance reported to be based and strength of recommendation
24. Neurological diseases – ALS, Parkinson's disease, stroke and MS	European Society for Clinical Nutrition and Metabolism 2017. ESPEN guideline clinical nutrition in neurology [58]	<ul style="list-style-type: none"> • Clinical <ul style="list-style-type: none"> o Early detection and treatment of problems that could lead to malnutrition in MS as it can compound fatigue • Behavioural <ul style="list-style-type: none"> o In people with ALS with muscular fatigue and long-lasting meals, advise to fractionate meals • Nutritional <ul style="list-style-type: none"> o Consider oral nutrition supplementation for prevention of malnutrition in MS o In people with ALS with muscular fatigue and long-lasting meals, advise to enrich meals and recommend nutritional supplementation if weight loss progresses <p>No fatigue-specific recommendations for Parkinson's disease or stroke</p>	<p>Good Practice Point – Strong consensus</p> <p>Good Practice Point – Strong consensus</p> <p>Strong consensus based on Grade B evidence – a body of evidence including high-quality systematic reviews of cohort or case-control studies or well-conducted cohort or case-control studies</p> <p>Good Practice Point – Strong consensus</p>
25. Stroke	Heart and Stroke Foundation 2019. Canadian stroke best practice recommendations: Mood, cognition, and fatigue following stroke [44]	<ul style="list-style-type: none"> • Clinical <ul style="list-style-type: none"> o Care should be by health professionals knowledgeable in fatigue and its management o Periodically screen for post-stroke fatigue o In those with post-stroke fatigue, screen for co-morbidities and medications associated with fatigue • Pharmacological <ul style="list-style-type: none"> o Some limited evidence that modafinil may be considered o Insufficient evidence to recommend antidepressant treatment for post-stroke fatigue • Information <ul style="list-style-type: none"> o Provide basic information about potential experience of post-stroke fatigue • Psychological <ul style="list-style-type: none"> o Cognitive behavioural therapy may be considered o Mindfulness-based stress reduction may be considered o Encourage patients to communicate energy status and rest needs to others • Behavioural <ul style="list-style-type: none"> o Counselling on graduated exercise schedules is recommended o Counselling on energy conservation strategies is recommended o Counselling on sleep hygiene is recommended o Provide education on pacing activity and rest 	<p>Level C – consensus and/or supported by limited research evidence</p> <p>Level C</p> <p>Level B – Evidence from single RCT or consistent findings from ≥ 2 well-designed non-randomized and/or non-controlled trials, and large observational studies</p> <p>Level C</p> <p>Level B</p> <p>Level B</p> <p>Level C</p> <p>Level C</p> <p>Level C</p> <p>Level B</p> <p>Level C</p>

(Continued)

Table 1. Continued.

Condition	Guideline organisation, date, and title	Summary of recommendations contained in the guidelines	Level of evidence on which guidance reported to be based and strength of recommendation
26. Stroke	Intercollegiate Stroke Working Party; 2023 National clinical guideline for stroke for the UK and Ireland [45]	<p>N.B. this information has been condensed and does not provide the full information in the guideline, for which it is necessary to access the source documents.</p> <ul style="list-style-type: none"> Clinical <ul style="list-style-type: none"> Assess and review for factors that may precipitate/exacerbate fatigue (e.g. depression, anxiety, sleep disorders, pain) Consider the impact of post-stroke fatigue and tailor scheduling and length of assessment and rehabilitation accordingly, and provide access to alternative solutions where necessary Pharmacological <ul style="list-style-type: none"> Fluoxetine should not be used to prevent post-stroke fatigue Modafinil should only be provided in the context of a clinical trial Information/education <ul style="list-style-type: none"> Provide information and education on how to prevent and manage fatigue and sources of support Behavioural – Consider for the following approaches: <ul style="list-style-type: none"> using a diary to record activities and fatigue Pacing and prioritising activities Rest Setting small goals Changing diet and/or exercise (tailored to individual) Psychological – Consider for the following approaches: <ul style="list-style-type: none"> building acceptance and adjustment relaxation and meditation coping methods Complementary <ul style="list-style-type: none"> Acupuncture should only be provided in the context of a clinical trial 	<p>Based on a combination of systematic reviews, primary studies, best practice guidelines, and expert consensus</p> <p>Clear evidence from high-quality systematic reviews and RCTs</p> <p>One small high-quality RCT</p> <p>Based on a combination of systematic reviews, primary studies, best practice guidelines, and expert consensus</p> <p>As above</p> <p>As above</p> <p>As above</p> <p>Systematic review but included studies were small with risk of bias</p>
27. Stroke	Stroke Foundation (2023). Clinical guidelines for stroke management [68]	<ul style="list-style-type: none"> Clinical <ul style="list-style-type: none"> Schedule therapy sessions for when patients are most alert Consider potential modifying factors for fatigue e.g. avoiding sedating drugs and alcohol, sleep-related sleep disorders, depression Information/education <ul style="list-style-type: none"> Provide information and education about fatigue and potential management strategies (details of strategies not provided) Behavioural <ul style="list-style-type: none"> Possible interventions could include exercise, improving sleep hygiene Psychological <ul style="list-style-type: none"> Possible interventions could include cognitive behavioural therapy 	<p>Consensus</p> <p>Consensus</p> <p>Consensus</p> <p>Consensus but insufficient evidence to guide practice</p> <p>Consensus but insufficient evidence to guide practice</p>
28. Respiratory conditions Chronic obstructive pulmonary disease	Global Initiative for Chronic Obstructive Lung Disease 2023. Global strategy for the prevention, diagnosis and management of chronic obstructive pulmonary disease 2023 report [69]	<ul style="list-style-type: none"> Behavioural <ul style="list-style-type: none"> Pulmonary rehabilitation Self-management education Nutritional <ul style="list-style-type: none"> Nutritional support Psychological <ul style="list-style-type: none"> Mind–body interventions 	<p>For all – Evidence Level B (RCTs with important limitations or limited body of evidence)</p>

Condition	Guideline organisation, date, and title	Summary of recommendations contained in the guidelines N.B. this information has been condensed and does not provide the full information in the guideline, for which it is necessary to access the source documents.	Level of evidence on which guidance reported to be based and strength of recommendation
29. Chronic obstructive pulmonary disease	Lung Foundation Australia, 2022. The COPD-X Plan: Australian and New Zealand guidelines for the management of chronic obstructive pulmonary disease 2022 [60]	<ul style="list-style-type: none"> • Clinical <ul style="list-style-type: none"> o Given the negative impact of exacerbations on symptoms such as fatigue, decide whether performing airway clearance techniques is appropriate, and if so, choose the most appropriate technique during exacerbations. Choice of techniques should be guided by a physiotherapist • Behavioural <ul style="list-style-type: none"> o Non-pharmacological strategies (such as pulmonary rehabilitation and regular exercise) should be provided to all patients • Behavioural <ul style="list-style-type: none"> o Rest your voice briefly to prevent voice fatigue, straining, and overuse 	Level of evidence not specified
30. Hoarseness	American Academy of Otolaryngology – Head and Neck Surgery Foundation, 2018. Clinical practice guideline: Hoarseness (Dysphonia) (Update) [71]	<ul style="list-style-type: none"> • Behavioural <ul style="list-style-type: none"> o Rest your voice briefly to prevent voice fatigue, straining, and overuse 	<p>Strong recommendation based on Level I evidence obtained from a systematic review of all relevant RCTs.</p> <p>Recommendation of high confidence based on Grade C evidence – observational studies, small-sample RCTs, expert opinion, and a preponderance of benefit over harm</p>

Environmental (physical) – One guideline (3.4%) for post-polio syndrome [67] recommended muscular training in a warm climate (Level B recommendation – “probably effective”).

Multicomponent – Two guidelines (6.9%), one for fibromyalgia [41] and one for MS [43], recommended multicomponent interventions that combine behavioural and psychological approaches. A weak recommendation for multicomponent therapies was made in fibromyalgia, based on a systematic review of moderate quality trials. A recommendation to consider a combination of aerobic and moderate progressive resistance activity with cognitive behavioural techniques for MS was based on evidence that ranged from very low to high quality.

Of the non-pharmacological treatments summarised above, only biofeedback and S-adenosyl methionine were advised against, both in relation to fibromyalgia [41].

Discussion

Statement of principal findings

Only 13.6% of clinical guidelines for long-term physical health conditions provided recommendations for how to manage fatigue. Furthermore, in guidelines that did address fatigue, the recommendations were often minimal, for example, advice to adjust medication if fatigue was a side-effect. Although recommendations for pharmacological treatment of fatigue were available for some conditions, the strong recommendations made were mainly about what treatments *not* to use whereas most of the recommendations for treatments to use were weak.

The most widely recommended non-pharmacological approach for fatigue was physical activity. The amount of advice given varied between guidelines, for example, in the type of exercise recommended and whether supervision is required but there was little advice on frequency or intensity of activity. The strength of recommendations varied, with few making strong recommendations; this does, however, suggest that guideline developers for other conditions should explore the evidence for physical activity on fatigue.

A variety of psychological approaches were recommended with no one dominant approach. No guideline advised against using psychological therapies, however, recommendations were mostly weak based on low-quality evidence.

Interpretation within the context of the wider literature

Most of the identified guidelines did not contain any recommendations for managing fatigue. For some guidelines, this is understandable because fatigue is not a major feature of those particular diseases. However, it should be borne in mind that while we did not identify fatigue prevalence data for all included LTCs (Supplementary table 1), this does not necessarily mean that people with those diseases do not experience fatigue. For example, it is widely recognised that people with thyroid disease experience fatigue [73], however, no prevalence data were found.

This review confirms that, where evidence is available, it has not always been incorporated into guidelines. As mentioned in the introduction, some evidence of benefit of interventions to alleviate fatigue exists in RA [21,26] and SLE [27]; however, only one of the five RA guidelines and one of the four SLE guidelines identified in this review included recommendations for fatigue management. Some trials have examined the effect of interventions on fatigue for people living with HIV but no guidelines were identified that have incorporated the findings [74,75]. A scoping review of systematic reviews reported that the anti-depressant

fluoxetine was found to be ineffective for reducing fatigue in HIV and post-stroke; however, the HIV guidelines we identified did not include this advice [46]. We have not reviewed evidence of efficacy of interventions to manage fatigue across all LTCs as this would be beyond the scope of this mapping review; however, these examples indicate that lack of guidance is not always due to non-availability of research evidence. It is also important that, where negative findings for treatments exist, they are incorporated into guidelines to advise on what not to do.

It is unclear why some guideline developers have not included recommendations in cases where evidence on the efficacy of interventions exists. Recommendations and checklists exist to help groups developing and updating clinical practice guidelines [76,77], and following these recommendations should help ensure that the included guidance is appropriate. However, it would seem that fatigue is not always identified by guideline developers as a priority. Patient involvement in the guideline development panel is crucial [78,79] but even where this occurred, for example in National Institute for Health and Care Excellence (NICE) RA guidelines [25], fatigue recommendations are not necessarily included. It is possible that this omission arises because of an assumption that symptoms of fatigue will be alleviated if the disease is otherwise brought under control, for example, if inflammation is controlled. This view may be mistaken as, for example, in RA [80] and inflammatory bowel disease [81], the correlation between disease activity and fatigue is low. Where fatigue is a persistent symptom of a LTC, it is important that guidelines should offer specific advice on how best to manage it.

Implications for policy, practice, and research

The scarcity of guidance for managing fatigue in LTCs is, however, likely to be at least partly explained by the limited available evidence for efficacy of pharmacological and non-pharmacological interventions. Much of the evidence reported in the included guidelines was rated fairly low quality, a finding that has also been identified elsewhere [46], highlighting the need to develop and test fatigue-management strategies in high-quality trials. There is a need to apply learning across LTCs, for example, to examine whether interventions that have been found to benefit one LTC could also benefit others. This would likely be facilitated by gaining a better understanding of the mechanisms of fatigue in different LTCs and any similarities and differences between conditions [82,83], which may also help to inform consideration of whether guidelines on fatigue management need to be disease-specific or could be developed across conditions or categories of conditions.

Strengths and limitations

Limitations of the review include that, owing to limited resources, the review included only guidelines published in English. Although we searched five bibliographic databases and six guideline repositories, limited resources also meant that there are other repositories that we did not search; our searches will therefore not have identified all guidelines for all long-term physical health conditions. In common with other mapping reviews [29], this study does not include a quality appraisal and therefore is not able to comment on the relative quality of individual guidelines.

Review strengths are that searches were conducted in both bibliographic databases and clinical guidelines repositories. Screening and a proportion of data extraction were conducted by two independent reviewers. This review identified a large number of guidelines across a wide range of LTCs; given the

consistency of the findings across LTCs, with few that incorporate recommendations for fatigue, unidentified studies are unlikely to threaten the review's conclusion that this is a neglected area within clinical guidelines.

Conclusions

Despite fatigue being a debilitating symptom for many people with a range of LTCs and a common reason for seeking help, clinicians have very little guidance about how best to help people suffering with fatigue.

There is a need for greater prioritisation of fatigue research so that practice recommendations can be improved to inform clinicians about better management of a symptom that is very difficult for patients.

Acknowledgements

N/A

Disclosure statement

No potential conflict of interest was reported by the author(s).

Funding

Unfunded.

Authors' contribution

KM, LR, and AB were involved in the conception of the work; KH, KM, and LR were involved in data acquisition; all authors were involved in the analysis and interpretation of data; all authors were involved in drafting or revising the manuscript and gave final approval of the submitted manuscript.

References

- [1] Hewlett S, Cockshott Z, Byron M, et al. Patients' perceptions of fatigue in rheumatoid arthritis: overwhelming, uncontrollable, ignored. *Arthritis Rheum.* 2005;53(5):697–702. doi: [10.1002/art.21450](https://doi.org/10.1002/art.21450).
- [2] Czuber-Dochan W, Dibley LB, Terry H, et al. The experience of fatigue in people with inflammatory bowel disease: an exploratory study. *J Adv Nurs.* 2013;69(9):1987–1999. doi: [10.1111/jan.12060](https://doi.org/10.1111/jan.12060).
- [3] Wade D, Besford J, Lowe D. The national audit of services for people with multiple sclerosis 2011. London: Royal College of Physicians; 2011.
- [4] Whitehead LC, Unahi K, Burrell B, et al. The experience of fatigue across long-term conditions: a qualitative meta-synthesis. *J Pain Symptom Manage.* 2016;52(1):131–143 e1. doi: [10.1016/j.jpainsymman.2016.02.013](https://doi.org/10.1016/j.jpainsymman.2016.02.013).
- [5] Oliva Ramirez A, Keenan A, Kalau O, et al. Prevalence and burden of multiple sclerosis-related fatigue: a systematic literature review. *BMC Neurol.* 2021;21(1):468. doi: [10.1186/s12883-021-02396-1](https://doi.org/10.1186/s12883-021-02396-1).
- [6] Gil-González I, Martín-Rodríguez A, Conrad R, et al. Quality of life in adults with multiple sclerosis: a systematic review. *BMJ Open.* 2020;10(11):e041249. doi: [10.1136/bmjopen-2020-041249](https://doi.org/10.1136/bmjopen-2020-041249).
- [7] Alikari V, Sachlas A, Gitrakou S, et al. Fatigue in arthritis: a multidimensional phenomenon with impact on quality of life: fatigue and quality of life in arthritis. *Adv Exp Med Biol.* 2017;987:243–256. doi: [10.1007/978-3-319-57379-3_22](https://doi.org/10.1007/978-3-319-57379-3_22).
- [8] Siciliano M, Trojano L, Santangelo G, et al. Fatigue in Parkinson's disease: a systematic review and meta-analysis. *Mov Disord.* 2018;33(11):1712–1723. doi: [10.1002/mds.27461](https://doi.org/10.1002/mds.27461).
- [9] Romberg-Camps MJ, Bol Y, Dagnelie PC, et al. Fatigue and health-related quality of life in inflammatory bowel disease: results from a population-based study in The Netherlands: the IBD-South Limburg cohort. *Inflamm Bowel Dis.* 2010;16(12):2137–2147. doi: [10.1002/ibd.21285](https://doi.org/10.1002/ibd.21285).
- [10] Yilmaz-Oner S, Ilhan B, Can M, et al. Fatigue in systemic lupus erythematosus: association with disease activity, quality of life and psychosocial factors. *Z Rheumatol.* 2017;76(10):913–919. doi: [10.1007/s00393-016-0185-0](https://doi.org/10.1007/s00393-016-0185-0).
- [11] Singh R, Teel C, Sabus C, et al. Fatigue in type 2 diabetes: impact on quality of life and predictors. *PLoS One.* 2016;11(11):e0165652. doi: [10.1371/journal.pone.0165652](https://doi.org/10.1371/journal.pone.0165652).
- [12] Chen YK, Qu JF, Xiao WM, et al. Poststroke fatigue: risk factors and its effect on functional status and health-related quality of life. *Int J Stroke.* 2015;10(4):506–512. doi: [10.1111/ijss.12409](https://doi.org/10.1111/ijss.12409).
- [13] Paddison JS, Effing TW, Quinn S, et al. Fatigue in COPD: association with functional status and hospitalisations. *Eur Respir J.* 2013;41(3):565–570. doi: [10.1183/09031936.00021412](https://doi.org/10.1183/09031936.00021412).
- [14] Stridsman C, Skär L, Hedman L, et al. Fatigue affects health status and predicts mortality among subjects with COPD: report from the population-based OLIN COPD study. *COPD.* 2015;12(2):199–206. doi: [10.3109/15412555.2014.922176](https://doi.org/10.3109/15412555.2014.922176).
- [15] Basu N, Yang X, Luben RN, et al. Fatigue is associated with excess mortality in the general population: results from the EPIC-Norfolk study. *BMC Med.* 2016;14(1):122. doi: [10.1186/s12916-016-0662-y](https://doi.org/10.1186/s12916-016-0662-y).
- [16] Rutkowski NA, Sabri E, Yang C. Post-stroke fatigue: a factor associated with inability to return to work in patients <60 years-A 1-year follow-up. *PLoS One.* 2021;16(8):e0255538. doi: [10.1371/journal.pone.0255538](https://doi.org/10.1371/journal.pone.0255538).
- [17] Druce KL, Aikman L, Dilleen M, et al. Fatigue independently predicts different work disability dimensions in etanercept-treated rheumatoid arthritis and ankylosing spondylitis patients. *Arthritis Res Ther.* 2018;20(1):96. doi: [10.1186/s13075-018-1598-8](https://doi.org/10.1186/s13075-018-1598-8).
- [18] Chen J, Taylor B, Palmer AJ, et al. Estimating MS-related work productivity loss and factors associated with work productivity loss in a representative Australian sample of people with multiple sclerosis. *Mult Scler.* 2019;25(7):994–1004. doi: [10.1177/1352458518781971](https://doi.org/10.1177/1352458518781971).
- [19] National Rheumatoid Arthritis Society. Invisible disease: Rheumatoid Arthritis and Chronic Fatigue Survey [Internet]. 2014. [cited 2017 Apr 4]. Available from: <https://nras.org.uk/product/invisible-disease-rheumatoid-arthritis-and-chronic-fatigue-survey/>.
- [20] Picariello F, Freeman J, Moss-Morris R. Defining routine fatigue care in Multiple Sclerosis in the United Kingdom: what treatments are offered and who gets them? *Mult Scler J Exp Transl Clin.* 2022;8(1):20552173211072274. doi: [10.1177/20552173211072274](https://doi.org/10.1177/20552173211072274).
- [21] Cramp F, Hewlett S, Almeida C, et al. Non-pharmacological interventions for fatigue in rheumatoid arthritis. *Cochrane Database Syst Rev.* 2013;(8):CD008322. doi: [10.1002/14651858.CD008322.pub2](https://doi.org/10.1002/14651858.CD008322.pub2).
- [22] Heine M, van de Port I, Rietberg MB, et al. Exercise therapy for fatigue in multiple sclerosis. *Cochrane Database Syst Rev.* 2015;2015(9):CD009956. doi: [10.1002/14651858.CD009956.pub2](https://doi.org/10.1002/14651858.CD009956.pub2).

- [23] Thomas S, Thomas PW, Kersten P, et al. A pragmatic parallel arm multi-centre randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based fatigue management programme (FACETS) for people with multiple sclerosis. *J Neurol Neurosurg Psychiatry*. 2013;84(10):1092–1099. doi: [10.1136/jnnp-2012-303816](https://doi.org/10.1136/jnnp-2012-303816).
- [24] Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. *Arthritis Care Res (Hoboken)*. 2021;73(7):924–939. doi: [10.1002/acr.24596](https://doi.org/10.1002/acr.24596).
- [25] National Institute for Health and Care Excellence. Rheumatoid arthritis in adults: management. NG100. 2018; [cited 2023 May 28].
- [26] Almeida C, Choy EHS, Hewlett S, et al. Biologic interventions for fatigue in rheumatoid arthritis. *Cochrane Database Syst Rev*. 2016;2016(6):CD008334. doi: [10.1002/14651858.CD008334.pub2](https://doi.org/10.1002/14651858.CD008334.pub2).
- [27] del Pino-Sedeño T, Trujillo-Martín MM, Ruiz-Irastorza G, et al. Effectiveness of nonpharmacologic interventions for decreasing fatigue in adults with systemic lupus erythematosus: a systematic review. *Arthritis Care Res (Hoboken)*. 2016;68(1):141–148. doi: [10.1002/acr.22675](https://doi.org/10.1002/acr.22675).
- [28] Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 Update of the EULAR recommendations for the management of systemic lupus erythematosus. *Ann Rheum Dis*. 2019;78(6):736–745. doi: [10.1136/annrheumdis-2019-215089](https://doi.org/10.1136/annrheumdis-2019-215089).
- [29] Clapton J, Rutter D, Sharif N. SCIE systematic mapping guidance. London: SCIE; 2009.
- [30] Pearson EJ, Morris ME, McKinstry CE. Cancer-related fatigue: appraising evidence-based guidelines for screening, assessment and management. *Support Care Cancer*. 2016;24(9):3935–3942. doi: [10.1007/s00520-016-3228-9](https://doi.org/10.1007/s00520-016-3228-9).
- [31] National Health and Medical Research Council. Guidelines [Internet]; [cited 2018 Sep 13]. Available from: <https://www.nhmrc.gov.au/guidelines>.
- [32] Canadian Medical Association. CPG Infobase: clinical practice guidelines [Internet]; [cited 2018 Sep 13]. Available from: <https://joulecma.ca/cpg/homepage>.
- [33] Guidelines International Network. International guidelines library [Internet]; [cited 2018 Sep 13]. Available from: <https://guidelines.ebmportal.com/>.
- [34] National Institute for Health and Care Excellence. Guidance [Internet]; [cited 2018 Sep 13]. Available from: <https://www.nice.org.uk/>.
- [35] ANZ Guideline Network. ANZ guidelines [Internet]; [cited 2018 Sep 13]. 2020. Available from: <https://anz-guideline-network.webnode.page/anz-guidelines/>
- [36] Scottish Intercollegiate Guidelines Network (SIGN). Our guidelines [Internet]; [cited 2018 Sep 13]. Available from: <https://www.sign.ac.uk/our-guidelines/>
- [37] Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan—a web and mobile app for systematic reviews. *Syst Rev*. 2016;5(1):210. doi: [10.1186/s13643-016-0384-4](https://doi.org/10.1186/s13643-016-0384-4).
- [38] Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting, and evaluation in health care. *Prev Med*. 2010;51(5):421–424. doi: [10.1016/j.ypmed.2010.08.005](https://doi.org/10.1016/j.ypmed.2010.08.005).
- [39] Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. *Gut*. 2019;68(Suppl 3):s1–s106. doi: [10.1136/gutjnl-2019-318484](https://doi.org/10.1136/gutjnl-2019-318484).
- [40] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. *J Hepatol*. 2009;51(2):237–267.
- [41] Macfarlane GJ, Kronisch C, Dean LE, et al. EULAR revised recommendations for the management of fibromyalgia. *Ann Rheum Dis*. 2017;76(2):318–328. doi: [10.1136/annrheumdis-2016-209724](https://doi.org/10.1136/annrheumdis-2016-209724).
- [42] Carsons SE, Vivino FB, Parke A, et al. Treatment guidelines for rheumatologic manifestations of Sjögren's syndrome: use of biologic agents, management of fatigue, and inflammatory musculoskeletal pain. *Arthritis Care Res (Hoboken)*. 2017;69(4):517–527. doi: [10.1002/acr.22968](https://doi.org/10.1002/acr.22968).
- [43] National Institute for Health and Care Excellence. Multiple sclerosis in adults: management. (NG220). 2022; [cited 2023 May30]. Available from: www.nice.org.uk/guidance/ng220/
- [44] Lanctôt KL, Lindsay MP, Smith EE, et al. Canadian Stroke Best Practice Recommendations: mood, cognition and fatigue following stroke, 6th edition update 2019. *Int J Stroke*. 2020;15(6):668–688. doi: [10.1177/1747493019847334](https://doi.org/10.1177/1747493019847334).
- [45] Intercollegiate Stroke Working Party. National clinical guideline for stroke for the UK and Ireland. London; 2023; [cited 2023 May30]. Available from: www.strokeguideline.org.
- [46] Hulme K, Safari R, Thomas S, et al. Fatigue interventions in long term, physical health conditions: a scoping review of systematic reviews. *PLoS One*. 2018;13(10):e0203367. doi: [10.1371/journal.pone.0203367](https://doi.org/10.1371/journal.pone.0203367).
- [47] Neill J, Belan I, Ried K. Effectiveness of non-pharmacological interventions for fatigue in adults with multiple sclerosis, rheumatoid arthritis, or systemic lupus erythematosus: a systematic review. *J Adv Nurs*. 2006;56(6):617–635. doi: [10.1111/j.1365-2648.2006.04054.x](https://doi.org/10.1111/j.1365-2648.2006.04054.x).
- [48] NHS. Complementary and alternative medicine [Internet]. 2022; [cited 2023 Jan 3]. Available from: [https://www.nhs.uk/conditions/complementary-and-alternative-medicine/#:~:text=Complementary%20and%20alternative%20medicine%20\(CAM,aromatherapy%2C%20meditation%20and%20colonic%20irrigation](https://www.nhs.uk/conditions/complementary-and-alternative-medicine/#:~:text=Complementary%20and%20alternative%20medicine%20(CAM,aromatherapy%2C%20meditation%20and%20colonic%20irrigation)
- [49] RHD Australia (ARF/RHD writing group). The 2020 Australian guideline for prevention, diagnosis and management of acute rheumatic fever and rheumatic heart disease. (3.2 edition, March 2022); [cited 2023 May 30] Available from: www.rhdaustralia.org.au/arf-rhd-guidelines
- [50] Ezekowitz JA, O'Meara E, McDonald MA, et al. 2017 Comprehensive update of the Canadian Cardiovascular Society Guidelines for the management of heart failure. *Can J Cardiol*. 2017;33(11):1342–1433. doi: [10.1016/j.cjca.2017.08.022](https://doi.org/10.1016/j.cjca.2017.08.022).
- [51] Achtstien RJ, Staal JB, van der Voort S, et al. Exercise-based cardiac rehabilitation in patients with chronic heart failure: a Dutch practice guideline. *Neth Heart J*. 2015;23(1):6–17. doi: [10.1007/s12471-014-0612-2](https://doi.org/10.1007/s12471-014-0612-2).
- [52] Bacon BR, Adams PC, Kowdley KV, et al. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. *Hepatology*. 2011;54(1):328–343. doi: [10.1002/hep.24330](https://doi.org/10.1002/hep.24330).
- [53] Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*. 2016;101(2):364–389. doi: [10.1210/jc.2015-1710](https://doi.org/10.1210/jc.2015-1710).
- [54] Centre for Research Excellence in Polycystic Ovary Syndrome (CREPCOS), European Society of Human Reproduction and Embryology (ESHRE), American Society of Reproductive Medicine (ASRM). International evidence based guideline for the assessment and management of polycystic ovary syndrome. Melbourne, Australia: Monash University; 2018.
- [55] Primary Care Guidelines Panel BC Centre for Excellence in HIV/AIDS. Primary care guidelines for the management of HIV/AIDS in British Columbia. British Columbia Centre for

- Excellence in HIV/AIDS; 2021; [cited 2023 May 30]. Available from: Primary-Care-Guidelines_NOV2022.pdf (bccfe.ca)
- [56] European AIDS Clinical Society. EACS guidelines version 10.1. 2020; [cited 2023 May 30]. Available from: https://www.eacsociety.org/media/guidelines-11.1_final_09-10.pdf
- [57] Gordon C, Amisssah-Arthur MB, Gayed M, et al. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. *Rheumatology (Oxford)*. 2018;57(1):e1–e45. doi: [10.1093/rheumatology/kex286](https://doi.org/10.1093/rheumatology/kex286).
- [58] Burgos R, Bretón I, Cereda E, et al. ESPEN guideline clinical nutrition in neurology. *Clin Nutr*. 2018;37(1):354–396. doi: [10.1016/j.clnu.2017.09.003](https://doi.org/10.1016/j.clnu.2017.09.003).
- [59] Stroke Foundation. Clinical guidelines for stroke management. Melbourne, Australia: Stroke Foundation; 2021.
- [60] Lung Foundation Australia. The COPD-X plan: Australian and New Zealand guidelines for the management of chronic obstructive pulmonary disease 2022; [cited 2023 May 30]. Available from: COPDX-V2-68-Q3-2022_FINAL.pdf.
- [61] Heidenreich PA, Bozkurt B, Aguilar D, et al. AHA/ACC/HFSA guideline for the management of heart failure. *J Am Coll Cardiol*. 2022;79(17):e263–e421. doi: [10.1016/j.jacc.2021.12.012](https://doi.org/10.1016/j.jacc.2021.12.012).
- [62] McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J*. 2021;42(36):3599–3726. doi: [10.1093/eurheartj/ehab368](https://doi.org/10.1093/eurheartj/ehab368).
- [63] Scottish Intercollegiate Guidelines Network (SIGN). Management of chronic heart failure. (SIGN publication no. 147). Edinburgh: SIGN; 2016.
- [64] Aschner P, Mauricio Muñoz O, Giron D, et al. Clinical practice guideline for the prevention, early detection, diagnosis, management and follow up of type 2 diabetes mellitus in adults. *Colomb Med (Cali)*. 2016;47(2):109–130. doi: [10.25100/cm.v47i2.2207](https://doi.org/10.25100/cm.v47i2.2207).
- [65] Bracchi M, van Halsema C, Post F, et al. British HIV Association guidelines for the management of tuberculosis in adults living with HIV 2018 (2021 interim update). 2021; [cited 2023 May 30]. Available from: <https://www.bhiva.org/TB-guidelines>
- [66] Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Disease Society of America. 2023; [cited 2023 May 30]. Available from: <https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-oi/guidelines-adult-adolescent-oi.pdf>
- [67] Farbu E, Gilhus NE, Barnes MP, et al. Post-polio syndrome. In Gilhus NE, Barnes MP, Brainin M, editors. *European handbook of neurological management*. 2nd ed. Blackwell Publishing Ltd. Chichester, UK; 2011. p. 311–319.
- [68] Stroke Foundation. Clinical guidelines for stroke management. 2023; [cited 2023 May 30]. Available from: <https://informme.org.au/guidelines/living-clinical-guidelines-for-stroke-management>
- [69] Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2023 report). 2023; [cited 2023 May 30]. 2023 GOLD Report - Global Initiative for Chronic Obstructive Lung Disease - GOLD (Available from: goldcopd.org)
- [70] Koninklijk Nederlands Genootschap voor Fysiotherapie (KNGF). KNGF guideline reumatoid arthritis. Koninklijk Nederlands Genootschap Voor Fysiotherapie; 2018.
- [71] Stachler RJ, Francis DO, Schwartz SR, et al. Clinical practice guideline: hoarseness (dysphonia) (update). *Otolaryngol Head Neck Surg*. 2018;158(1_suppl): S1–S42.
- [72] International Diabetes Federation and DAR International Alliance. Diabetes and Ramadan: practical guidelines. Brussels, Belgium: International Diabetes Federation; 2021.
- [73] British Thyroid Foundation. Coping with fatigue [Internet]. 2022; [cited 2022 Jan 11]. Available from: <https://www.btf-thyroid.org/coping-with-fatigue>
- [74] Xiao X, Reynolds NR, Saligan L, et al. Effectiveness of non-pharmacological interventions to decrease fatigue in people living with HIV/AIDS: a protocol of systematic review and meta-analysis. *BMJ Open*. 2020;10(9):e040996. doi: [10.1136/bmjopen-2020-040996](https://doi.org/10.1136/bmjopen-2020-040996).
- [75] Jong E, Oudhoff LA, Epskamp C, et al. Predictors and treatment strategies of HIV-related fatigue in the combined antiretroviral therapy era. *AIDS*. 2010;24(10):1387–1405. doi: [10.1097/QAD.0b013e328339d004](https://doi.org/10.1097/QAD.0b013e328339d004).
- [76] Schünemann HJ, Wiercioch W, Etzemandia I, et al. Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise. *CMAJ*. 2014;186(3):E123–E142. doi: [10.1503/cmaj.131237](https://doi.org/10.1503/cmaj.131237).
- [77] Sanabria AJ, Pardo-Hernandez H, Ballesteros M, et al. The UpPriority tool was developed to guide the prioritization of clinical guideline questions for updating. *J Clin Epidemiol*. 2020;126:80–92. doi: [10.1016/j.jclinepi.2020.06.018](https://doi.org/10.1016/j.jclinepi.2020.06.018).
- [78] Guidelines International Network and McMaster University. GIN-McMaster guideline development checklist. 2022; [cited 2023 Jan 3]. Available from: <https://cebgrade.mcmaster.ca/guidelinechecklistonline.html#GuidelineGroupMembershiptable>
- [79] Guerra-Farfan E, Garcia-Sanchez Y, Jornet-Gibert M, et al. Clinical practice guidelines: the good, the bad, and the ugly. *Injury*. 2022;54(Suppl 3):S26–S29. doi: [10.1016/j.injury.2022.01.047](https://doi.org/10.1016/j.injury.2022.01.047).
- [80] Pope JE. Management of fatigue in rheumatoid arthritis. *RMD Open*. 2020;6(1):e001084. doi: [10.1136/rmdopen-2019-001084](https://doi.org/10.1136/rmdopen-2019-001084).
- [81] Villoria A, García V, Dosal A, et al. Fatigue in out-patients with inflammatory bowel disease: prevalence and predictive factors. *PLoS One*. 2017;12(7):e0181435. doi: [10.1371/journal.pone.0181435](https://doi.org/10.1371/journal.pone.0181435).
- [82] Matura LA, Malone S, Jaime-Lara R, et al. A systematic review of biological mechanisms of fatigue in chronic illness. *Biol Res Nurs*. 2018;20(4):410–421. doi: [10.1177/1099800418764326](https://doi.org/10.1177/1099800418764326).
- [83] Jaime-Lara RB, Koons BC, Matura LA, et al. A qualitative metasynthesis of the experience of fatigue across five chronic conditions. *J Pain Symptom Manage*. 2020;59(6):1320–1343. doi: [10.1016/j.jpainsymman.2019.12.358](https://doi.org/10.1016/j.jpainsymman.2019.12.358).
- [84] Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ*. 2008;336(7650):924–926. doi: [10.1136/bmj.39489.470347.AD](https://doi.org/10.1136/bmj.39489.470347.AD).
- [85] Ebell MH, Siwek J, Weiss BD, et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. *J Am Board Fam Pract*. 2004;17(1):59–67. doi: [10.3122/jabfm.17.1.59](https://doi.org/10.3122/jabfm.17.1.59).
- [86] Brainin M, Barnes M, Baron JC, et al. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces—revised recommendations 2004. *Eur J Neurol*. 2004;11(9):577–581. doi: [10.1111/j.1468-1331.2004.00867.x](https://doi.org/10.1111/j.1468-1331.2004.00867.x).
- [87] Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. *BMJ*. 2001;323(7308):334–336. doi: [10.1136/bmj.323.7308.334](https://doi.org/10.1136/bmj.323.7308.334).

Appendix A

The following search strategy was used to identify eligible papers:

1. Guideline* or guidance in Title
2. MeSH DESCRIPTOR Fatigue Explode all
3. MeSH DESCRIPTOR long-term conditions Explode all
4. MeSH DESCRIPTOR chronic disease Explode all
5. MeSH DESCRIPTOR chronic illness Explode all
6. Multiple sclerosis
7. Parkinson's
8. Stroke
9. Polio
10. Epilepsy
11. Rheumatoid arthritis
12. Osteoarthritis
13. Charcot-Marie tooth
14. Systemic lupus erythema
15. Lupus
16. COPD
17. Asthma
18. Heart failure
19. Inflammatory bowel disease
20. Diabetes
21. Thyroid
22. Sickle cell
23. HIV
24. Hepatitis B
25. Hepatitis C
26. Kidney disease
27. Liver disease
28. #1 and #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27